Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 6661 to 6675 of 7680 results

  1. Glaucoma - lerdelimumab (CAT-152) [ID383]

    In development [GID-TAG381] Expected publication date: TBC

    Technology appraisal guidance
    In development

  2. Benralizumab for treating eosinophilic oesophagitis in people aged 12 to 65 [ID5093]

    In development [GID-TA10995] Expected publication date: TBC

    Technology appraisal guidance
    In development

  3. Pembrolizumab with enzalutamide for treating metastatic hormone-relapsed prostate cancer [ID5103]

    In development [GID-TA11004] Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Breast cancer (metastatic) -trastuzumab (as monotherapy and in combination with a taxane) [ID345]

    Discontinued [GID-TAG417]

    Technology appraisal guidance
    Discontinued

  5. Ticagrelor for preventing cardiovascular events in people with type 2 diabetes and coronary artery disease [ID1514]

    Discontinued [GID-TA10429]

    Technology appraisal guidance
    Discontinued

  6. Multiple myeloma - carfilzomib (with lenalidomide and dexamethasone, after prior therapy) [ID677]

    Discontinued [GID-TAG511]

    Technology appraisal guidance
    Discontinued

  7. Macular oedema (diabetic) - pegaptanib sodium [ID452]

    Discontinued [GID-TAG280]

    Technology appraisal guidance
    Discontinued

  8. Serelaxin for the treatment of acute decompensated heart failure [ID673]

    Discontinued [GID-TAG454]

    Technology appraisal guidance
    Discontinued

  9. Colorectal cancer (metastatic) - MABp1 (after previous treatment) [ID917]

    Discontinued [GID-TA10065]

    Technology appraisal guidance
    Discontinued

  10. Pembrolizumab with chemotherapy for untreated metastatic urothelial cancer ID1545

    Discontinued [GID-TA10418]

    Technology appraisal guidance
    Discontinued

  11. L-glutamine for preventing painful crises in sickle cell disease in people aged 5 years and over [ID1523]

    Discontinued [GID-TA10452]

    Technology appraisal guidance
    Discontinued

  12. Colon cancer (adjuvant) - irinotecan [ID379]

    In development [GID-TAG380] Expected publication date: TBC

    Technology appraisal guidance
    In development

  13. Rucaparib for treating ovarian, fallopian tube or peritoneal cancer that has a BRCA mutation [ID1184]

    Discontinued [GID-TA10168]

    Technology appraisal guidance
    Discontinued

  14. Multiple myeloma (one prior therapy) - vorinostat (with bortezomib) [ID501]

    Discontinued [GID-TAG435]

    Technology appraisal guidance
    Discontinued

  15. Cediranib for treating relapsed platinum-sensitive ovarian, fallopian tube or primary peritoneal cancer [ID790]

    Discontinued [GID-TA10018]

    Technology appraisal guidance
    Discontinued